OncLive TV

Meredith Buxton, PhD, research director, assistant professor, University of California, San Francisco School of Medicine, discusses the I-SPY 2 trial for patients with HER2-positive breast cancer.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

Stephen S. Grubbs, MD, senior director of the new clinical affairs department of the American Society of Clinical Oncology (ASCO) discusses value-based oncology.

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer.

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.

Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Andrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Michael A. Thompson, MD, PhD, oncology/hematology, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses easy steps for oncologists to start using social media.

Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.